Evaluarea eficacităţii şi toleranței preparatului Abactal (Firma Lek Pharmaceuticals DD) în tratamentul infecţiilor tractului urinar

Dumbraveanu, I.; Tanase, A.; Lupaşco, C.; Popov, M.; Romanciuc, Gr.; Punga, V.

dc.contributor.author	Dumbraveanu, I.
dc.contributor.author	Tanase, A.
dc.contributor.author	Lupaşco, C.
dc.contributor.author	Popov, M.
dc.contributor.author	Romanciuc, Gr.
dc.contributor.author	Punga, V.
dc.date.accessioned	2022-04-20T11:30:25Z
dc.date.available	2022-04-20T11:30:25Z
dc.date.issued	2002
dc.identifier.citation	DUMBRAVEANU, I., TANASE, A., LUPAŞCO, C., POPOV, M., ROMANCIUC, Gr., PUNGA, V. Evaluarea eficacităţii şi toleranței preparatului Abactal (Firma Lek Pharmaceuticals DD) în tratamentul infecţiilor tractului urinar. In: Dializa și Transplant Renal din Republica Moldova: conferința 3-a de Urologie, conferința 2-a de Nefrologie: culegere de lucrări. Chișinău, 2002, pp. 6-9.
dc.identifier.uri	http://repository.usmf.md/handle/20.500.12710/20408
dc.description.abstract	Summary UTI is one major problem in the medicine. In treatment of UTI multiple therapeutic schemes are folowed. 32 patients with acute and cronic UTI were treated using antibacterial monoterapy with Abactal (LEK Pharmaceuticals dd). Positive rezults were found in 28 patients. While no change from the prescristing condition was found in 4 (12%). Tolerance was found to be good in 84% patients. Adverse effect were found in 16% patients. This antibactherial preparation has opened a new perspective in the treatment of patients with urinary tract infection.	en_US
dc.language.iso	ro	en_US
dc.publisher	Societatea Urologilor din Republica Moldova	en_US
dc.relation.ispartof	Culegere de lucrări Conferința 3-a de Urologie, Conferința 2-a de Nefrologie: Dializa și Transplant Renal din Republica Moldova (30 - 31 octombie 2002)	en_US
dc.title	Evaluarea eficacităţii şi toleranței preparatului Abactal (Firma Lek Pharmaceuticals DD) în tratamentul infecţiilor tractului urinar	en_US
dc.type	Article	en_US